FDA Pediatric Extrapolation: Analysis Using FDA Clinical Trial Data

Overview

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-

How To Apply Connect with ORISE…on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A Complete Application Consists Of

• An application
• Transcripts —  for detailed information about acceptable transcripts
• A current resume/CV, including academic history, employment history, relevant experiences, and publication list
• One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER. Please include the reference code for this opportunity in your email.

Final date to receive applications 4/30/2026 3:00:00 PM Eastern Time Zone

Description

Applications will be reviewed on a rolling-basis.

FDA Office and

Location:

A research opportunity is available at the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of New Drugs (OND) Office of Immunology and Inflammation (OII), located in Silver Spring, Maryland. The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States.

As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.

Research Project: Extrapolation relies on the use of inferences about efficacy in children often based on data in adults based on assumptions or evidence of disease and response similarity between adults and children. The critical need to systematically assess extrapolation assumptions is well recognized in pediatric drug development. The FDA has access to data from approximately 1,200 pediatric clinical trials of which data from 600 trials spanning over 300 pediatric development programs will allow disease-focused systematic review.

These data can provide the basis for an extrapolation framework of adult clinical trial information in pediatric drug evaluation. The proposed project is aimed at analyzing adult and pediatric clinical trials to verify assumptions underlying extrapolation of efficacy.

Educational and Training Components: The fellow will be involved in the following activities related to the research project: participate in data collection from public and proprietary sources, analyze research data, and contribute to presentation/publication of research findings.

Learning Objectives: Under the guidance of the mentor(s), you will be involved in a systematic review of adult and pediatric hypertension trials with a focus on patients less than 6 years of age. You will learn to study similarities of disease between adults and children; understand expected treatment response differences in children, if any; you will assess possibility of borrowing information from previous studies (adult and pediatric) and provide a framework for optimizing trials.

Mentor: The mentor for this opportunity is Lily (Yeruk) Mulugeta (yeruk.mulugeta.gov). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment

Start Date:

July 2026. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full-time, in-person at the FDA White Oak Campus in Silver Spring, Maryland.

Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience.

Citizenship Requirements: This opportunity is available to U.S. citizens only.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will…